About this trial
This clinical trial aims to learn the impact of dexmedetomidine on the minimum alveolar concentration blunting the adrenergic response (MAC-BAR) of sevoflurane to carbon dioxide pneumoperitoneum in patients undergoing laparoscopic cholecystectomy. It will also learn about the effect of dexmedetomidine on hemodynamic parameters. The main questions are:
* Does dexmedetomidine reduce the MAC-BAR of sevoflurane required to suppress the sympathetic response to carbon dioxide pneumoperitoneum? * Would dexmedetomidine administration dose-dependently reduce the minimum alveolar concentration blunting the adrenergic response of sevoflurane required to suppress the sympathetic response to carbon dioxide pneumoperitoneum? Researchers will compare low-dose dexmedetomidine to high-dose dexmedetomidine to see if dexmedetomidine works to treat postoperative negative behavior change and emergence delirium.
Participants will:
* Take intravenous dexmedetomidine or 0.9% saline (a look-alike substance that contains no drug) * Study drug infusions were initiated 15 minutes prior to anesthesia induction, allowing a minimum of 30 minutes to elapse before surgical incision to achieve steady-state plasma and brain concentrations.
Eligibility criteria
Qualifiers
1. Aged 18-45 years.
2. American Society of Anesthesiologists (ASA) grade I - II.
3. Patients undergoing elective laparoscopic cholecystectomy.
Disqualifiers
1. Inability to provide informed consent;
2. History of chronic pain or substance abuse;
3. Pregnancy;
4. Body mass index (BMI) ≥ 30 kg/m2;
Trial design
Treatments tested in this trial
- Dexmedetomidine low-dose
- normal Saline
- Dexmedetomidine high-dose